The competitor Ozempique Mounjaro becomes even more popular - this is why
Mounjaro's active ingredient, shooting, could become a major bestseller, according to experts.
In terms of weight loss drugs, the treatment of Novo Nordisk type 2 diabetes Ozempic - And her sister medicine for weight loss, Wegovy - are usually the first ones who come to mind. But in light of the rise of these drugs as a popular solution to lose weight, competitors want a market share. Eli Lilly now has comparable options in the form of Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight loss), which both contain the same active ingredient, shooting. And while the semaglutide - the active ingredient of Wegovy and Ozempic - dominated the market, the shooting becomes even more popular.
In relation: Ozempic patients say that "stops working" for weight loss - how to prevent this .
The shooting was approved by the US Food and Drug Administration (FDA) for type 2 diabetes under the trade name Mounjaro in 2022, but the medication is often prescribed out of AMM for weight loss, just like ozempic. Last month, the shooting was also Approved for chronic weight management Under the Zepbound brand.
To help weight loss, the drug activates two hormonal receptors called Peptide-1 type glucagon (GLP-1) and insulinotropic polypeptide (GIP) dependent on glucose to reduce hunger and food supply, according to the FDA. This differs from the Ozempic and the Wegovy, which only imitate the effects of a hormone , GLP-1.
Tirzepatide has since distinguished semaglutide treatments, with new research suggesting that it is more efficient In a study by Truveta Research. Released on November 22 (and not yet evaluated by peers), the study revealed that after a year of treatment, patients taking shooting were " much more likely "To reach 5%, 10% and 15% weight loss compared to those who have semaglutide. They were also more likely to lose weight in brands of three, six months and 12 months.
Regarding diabetes, another study funded by Eli Lilly revealed that the shooting has resulted in a greater reduction in blood sugar In addition to more weight loss when Compared to semaglutide ,, The New York Times reported. (It should be noted that the study compared different doses.)
In light of promising results, Next year alone , Morgan Stanley predicts that Zepbound will achieve $ 2.2 billion in sales, while Bank of America puts this even higher number, to 2.7 billion dollars, CNBC reported. By 2029, Mounjaro should have sales totaling $ 27 billion, representing Growth of 36% , by Biopharméctoror. This eclipses the projection of ozempic over the next seven years, as the drug should increase by 6.5%.
As CNBC reported, Wall Street is enthusiastic by Zepbound because it could cause more weight loss than Wegovy, but data comparing the two is necessary to confirm it. Reuters reported that a Tête-à-tête trial The comparison of Zepbound and Wegovy in patients with obesity or overweight is led by Eli Lilly, and results are expected in 2025.
In relation: The ozempic patient reveals a new "repulsive" side effect .
Speak with biopharmareporter Kevin Marcaida , the pharmaceutical analyst at Globaldata, said that in the short term, we can still expect Ozempic to direct sales because it was approved five years before Mounjaro. However, by 2027, Mounjaro should pass Ozempic in front of its demonstrated clinical efficiency. Growth will also be helped by recent shooting approval for weight loss under the Zepbound brand, the point of sale reported. AE0FCC31AE342FD3A1346EBB1F342FCB
Beyond the release of Ozempic, Marcaida plans that Mounjaro / Zepbound will also be at best other brands: reading sales on the diabetes and obesity market by 2029. Seamus Fernandez , a Guggenheim analyst offered a prediction similar to that of Marcaida, saying to CNBC that shooting has "a very strong photo of being the best -selling molecule of all time in the pharmaceutical industry".
But that does not mean that other brands will not see growth too. According to CNBC, Wegovy can be as a rise if it receives the approval of expanded use for heart health in the United States and Europe, CNBC reported. If it is awarded, it would be the first GLP-1 drug to receive this approval, Eduardo Grunvald , MD, medical director of the Center for Advanced Weight Management of the UC San Diego, told The Outlet. Beyond that, this could exert additional pressure on insurance companies to cover this type of treatment.
In total, analysts provide that the overall weight loss drug market will continue to develop, possibly reach $ 100 billion By 2030, CNBC reported. Those of Goldman Sachs also predict that around 15 million American adults will take these drugs in the same period of time.
In relation: For more information, register for our daily newsletter .
Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.
